About: Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats
Creator	Tan, Wenjie Wang, Wenling Huang, Baoying Li, • Wang, •
Source	Medline; PMC
abstract	Conventional influenza vaccines need to be designed and manufactured yearly. However, they occasionally provide poor protection owing to antigenic mismatch. Hence, there is an urgent need to develop universal vaccines against influenza virus. Using nucleoprotein (NP) and extracellular domain of matrix protein 2 (M2e) genes from the influenza A virus A/Beijing/30/95 (H3N2), we constructed four recombinant vaccinia virus-based influenza vaccines carrying NP fused with one or four copies of M2e genes in different orders. The recombinant vaccinia viruses were used to immunize BALB/C mice. Humoral and cellular responses were measured, and then the immunized mice were challenged with the influenza A virus A/Puerto Rico/8/34 (PR8). NP-specific humoral response was elicited in mice immunized with recombinant vaccinia viruses carrying full-length NP, while robust M2e-specific humoral response was elicited only in the mice immunized with recombinant vaccinia viruses carrying multiple copies of M2e. All recombinant viruses elicited NP- and M2e-specific cellular immune responses in mice. Only immunization with RVJ-4M2eNP induced remarkably higher levels of IL-2 and IL-10 cytokines specific to M2e. Furthermore, RVJ-4M2eNP immunization provided the highest cross-protection in mice challenged with 20 MLD(50) of PR8. Therefore, the cross-protection potentially correlates with both NP and M2e-specific humoral and cellular immune responses induced by RVJ-4M2eNP, which expresses a fusion antigen of full-length NP preceded by four M2e repeats. These results suggest that the rational fusion of NP and multiple M2e antigens is critical toward inducing protective immune responses, and the 4M2eNP fusion antigen may be employed to develop a universal influenza vaccine. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12250-019-00138-9) contains supplementary material, which is available to authorized users.
has issue date	2019-06-25(xsd:dateTime)
bibo:doi	10.1007/s12250-019-00138-9
bibo:pmid	31240620
has license	no-cc
sha1sum (hex)	1fc272e29cf664fd24c582541095b47dcaca7f5f
schema:url	https://doi.org/10.1007/s12250-019-00138-9
resource representing a document's title	Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats
has PubMed Central identifier	PMC6814692
has PubMed identifier	31240620
schema:publication	Virol Sin
resource representing a document's body	covid:1fc272e29cf664fd24c582541095b47dcaca7f5f#body_text
is schema:about of	named entity 'extracellular domain' named entity 'recombinant' named entity 'orders' named entity 'These' named entity 'PROTECTION' named entity 'EMPLOYED' named entity 'FUSION' named entity 'VACCINIA' named entity 'VACCINES' named entity 'DIFFERENT' named entity 'OCCASIONALLY' named entity 'ELICITED' named entity 'COPIES' named entity 'PROTECTION' named entity 'ROBUST' named entity 'RECOMBINANT VACCINIA VIRUS' named entity 'IL-2' named entity 'IMMUNE RESPONSES' named entity 'INFLUENZA A VIRUS' named entity 'CROSS' named entity 'IMMUNIZED' named entity 'IMMUNIZATION' named entity 'USED' named entity 'ANTIGENS' named entity 'USING' named entity 'CARRYING' named entity 'MULTIPLE' named entity 'MATRIX PROTEIN 2' named entity 'UNIVERSAL' named entity 'MLD' named entity 'CONSTRUCTED' named entity '2F8' named entity 'M2E' named entity 'INDUCED' named entity 'ORDERS' named entity 'PR8' named entity 'BASED' named entity 'RESULTS' named entity 'RECOMBINANT' named entity 'SPECIFIC' named entity 'RECOMBINANT' named entity 'NEED' named entity 'REPEATS' named entity 'POOR' named entity 'MANUFACTURED' named entity 'HIGHEST' named entity 'MEASURED' named entity 'NUCLEOPROTEIN' named entity 'GENES' named entity 'SUGGEST' named entity 'URGENT' named entity 'CROSS' named entity 'TANDEM REPEATS' named entity 'INFLUENZA VIRUS' named entity 'USING' named entity 'ECTODOMAIN' named entity 'INDUCING' named entity 'MISMATCH' named entity 'PRECEDED' named entity 'MAY BE' named entity 'HUMORAL RESPONSE' named entity 'FUSED WITH' named entity 'RICO' named entity 'CONVENTIONAL' named entity 'LEVELS' named entity 'CYTOKINES' named entity 'IL-10' named entity 'INFLUENZA VIRUS' named entity 'INFLUENZA VACCINES' named entity 'YEARLY' named entity 'HIGHER' named entity 'INFLUENZA VACCINE' named entity 'ANTIGEN' named entity 'EXTRACELLULAR DOMAIN' named entity 'RESPONSES' named entity 'VIRUSES' named entity 'CELLULAR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software